Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.

Cardiovascular and metabolic safety profiles of the fluoroquinolones / A. Pugi;L. Longo;A. Bartoloni;G. M. Rossolini;A. Mugelli;A. Vannacci;F. Lapi. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - ELETTRONICO. - 11:(2012), pp. 53-69. [10.1517/14740338.2011.624512]

Cardiovascular and metabolic safety profiles of the fluoroquinolones.

PUGI, ALESSANDRA;BARTOLONI, ALESSANDRO;ROSSOLINI, GIAN MARIA;MUGELLI, ALESSANDRO;VANNACCI, ALFREDO;LAPI, FRANCESCO
2012

Abstract

Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.
2012
11
53
69
A. Pugi;L. Longo;A. Bartoloni;G. M. Rossolini;A. Mugelli;A. Vannacci;F. Lapi
File in questo prodotto:
File Dimensione Formato  
067 2011 Pugi FQ Review.pdf

Accesso chiuso

Descrizione: Articolo
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 333.97 kB
Formato Adobe PDF
333.97 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/594742
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 9
social impact